Abstract
The need for safe and effective antiplatelet agents motivates scientists towards a non-ceasing research which has through the past few years provided patients suffering from coronary artery disease, submitted or not to percutaneous intervention or heart surgery with safe and life-saving pharmaca; after ticlopidine and clopidogrel and just recently, ticagrelor and prasugrel have been developed with the aim to provide adequate protection against thrombotic cardiovascular episodes and avoid significant bleeding events. Herein, we are presenting through an updated literature research and recent patents data the novel agents ticagrelor and prasugrel, which promise improved effectiveness combined with an increased level of safety.
Keywords: ADP inhibitor, antiplatelet agent, cardiovascular events, clopidogrel, prasugrel, ticagrelor, coronary artery disease, heart surgery, ticlopidine, thrombotic cardiovascular episodes, AZD6140, adenosine diphosphate, dyspnea, arrhythmias, thienopyridines, acute coronary syndromes, Thrombolysis in Myocardial Infarction, atherosclerotic disease, PLATO, DISPERSE II, ONSET/OFFSET, TRITON-TIMI 38, JUMBO-TIMI 26, ventricular pauses
4